{"id":647,"date":"2020-03-16T16:31:02","date_gmt":"2020-03-16T16:31:02","guid":{"rendered":"https:\/\/www.pharmity.com\/?p=647"},"modified":"2020-03-16T16:54:01","modified_gmt":"2020-03-16T16:54:01","slug":"clinical-trials-challenges-in-relation-to-covid-19","status":"publish","type":"post","link":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/","title":{"rendered":"Clinical Trials Challenges in relation to COVID-19"},"content":{"rendered":"\n<h5 style=\"text-align: justify;\"><strong><span style=\"color: #808080;\"><em>The COVID-19 dissemination is highly impacting the lives of all of us, personally and professionally and we still do not know how this situation will progress and when we could go back to normality.<\/em><\/span><\/strong><\/h5>\n<h5 style=\"text-align: justify;\"><strong><span style=\"color: #808080;\"><em>Working on clinical research, we need to keep on working to safeguard first the safety and well-being of all those patients currently participating in a clinical trial, and to protect their rights.<\/em><\/span><\/strong><\/h5>\n<h5 style=\"text-align: justify;\"><strong><span style=\"color: #808080;\"><em>The Regulatory Authorities need to be more proactive than never, be flexible and provide right directions in order to protect the patients.<\/em><\/span><\/strong><\/h5>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<h3><span style=\"color: #48c2a5;\"><strong>Sponsor Oversight\u00a0<\/strong><\/span><\/h3>\n<h5 style=\"text-align: justify;\">The sponsors oversight activities such as monitoring, or GCP site audits, cannot be stopped but they need to be adapted. The MHRA highlighted in an interesting <span style=\"text-decoration: underline;\"><strong><span style=\"color: #0000ff; text-decoration: underline;\"><a style=\"color: #0000ff; text-decoration: underline;\" href=\"https:\/\/mhrainspectorate.blog.gov.uk\/2020\/03\/12\/advice-for-management-of-clinical-trials-in-relation-to-coronavirus\/\" target=\"_blank\" rel=\"noopener noreferrer\">post<\/a><\/span><\/strong><\/span> published on the 12th March 2016, that alternative oversight mechanisms can be introduced to ensure ongoing subject safety and well-being, providing the following considerations are taken:<\/h5>\n<ul style=\"text-align: justify;\">\n<li>\n<h5>First to conduct a brief <span style=\"color: #c45e16;\"><strong><u>risk assessment<\/u><\/strong><\/span> and document the impact of the alternative approach.<\/h5>\n<\/li>\n<li>\n<h5>Prioritize by those <span style=\"color: #c45e16;\"><strong><u>critical activities<\/u><\/strong><\/span> such as <span style=\"color: #c45e16;\"><strong><u>safety<span style=\"color: #000000;\">.<\/span><\/u><\/strong><\/span><\/h5>\n<\/li>\n<li>\n<h5>Remote monitoring can be considered given that it does not place an <span style=\"color: #c45e16;\"><strong><u>extra burden<\/u><\/strong><\/span> on trial sites.<\/h5>\n<\/li>\n<li>\n<h5>Subjects must <span style=\"color: #c45e16;\"><strong><u>consent<\/u><\/strong> <\/span>to any sharing of their personal information outside the trial site.<\/h5>\n<\/li>\n<\/ul>\n<h5 style=\"text-align: justify;\">It is important to mention that not all the countries allow to access remotely the patients\u2019 medical records and that the alternative plans should consider the country specific data privacy regulations. Even if it would be possible to access pseudonymized medical records remotely, it still will not be an easy task since robust procedures and information security controls should be in place to ensure the safety of the subjects\u2019 records.<\/h5>\n<h5 style=\"text-align: justify;\">The MHRA pointed on their post \u201cphone calls, video calls\u201d as an alternative mechanism. Caution should be taken (as per the explanation above) if using a video call to avoid accessing details a monitor\/auditor should not read or to restrict the possibility of capturing screenshots.<\/h5>\n<h5 style=\"text-align: justify;\">A risk assessment is definitely the right start, but it is further recommended <span style=\"color: #c45e16;\"><strong>to discuss the pros\/cons of the alternative approach with the relevant Ethics Committee<\/strong><\/span>. Discuss with them how the site could be accessed remotely and whether the consent process needs to be amended.<\/h5>\n<h5 style=\"text-align: justify;\">Other Regulatory Authorities such AEMPS (Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios) in Spain have started giving some initial directions to the Pharmaceutical Industry regarding how to handle the clinical trials in response to the multiple queries recently raised to the Spanish Medicines Agency (Exceptional Measures Proposal for a maximum period of four months). The note has not yet been officially published but one of their proposed measures, for example, is the following one regarding monitoring visits:<\/h5>\n<h5 style=\"text-align: justify;\"><em>\u201cIt is recommended to the sponsor updating the clinical trial monitoring plans for the next four months, prioritizing the centralized and remote monitoring of the participating sites which does not include source data verification. To the extent possible, the source data verification should be postponed until it is possible to access the medical records onsite. The sponsor will agree with the sites and participating teams the conditions surrounding those monitoring activities\u201d.<\/em><\/h5>\n<blockquote>\n<h4><span style=\"color: #808080;\"><strong>Regulatory Authorities must provide clear instructions and expectations<\/strong><\/span><\/h4>\n<\/blockquote>\n\n\n\n<h3>&nbsp;<\/h3>\n<h3><span style=\"color: #48c2a5;\"><strong>Conclusion<\/strong><\/span><\/h3>\n<h5 style=\"text-align: justify;\">The Regulatory Authorities perform an essential role in the quality of a trial. They need to establish the requirements and provide clear guidance, defining the minimal expectations on how to manage the clinical trials under the current situation. The main goal now is subject safety but without forgetting data integrity.<\/h5>\n<h5 style=\"text-align: justify;\">Given this, the amount of clarity that the RA provide will determine the ease that sponsors, and third parties, investigators, and trial participants have in understanding how to act with the less harm possible.<\/h5>\n<p>&nbsp;<\/p>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<h6><span style=\"color: #48c2a5;\"><strong>Author: Dr Leire Z\u00fa\u00f1iga, Director and Principal GCP <\/strong><strong>Consultant<\/strong><\/span><\/h6>\n<h6><span style=\"color: #48c2a5;\"><strong>PHARMITY, 16<sup>th<\/sup> March 2020<\/strong><\/span><\/h6>\n<h6><a href=\"http:\/\/www.pharmity.com\">www.pharmity.com<\/a><\/h6>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":656,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ich-gcp"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Clinical Trials Challenges in relation to COVID-19 - Pharmity<\/title>\n<meta name=\"description\" content=\"ICH GCP Renovation. The way forward | This article will explain the ICH revision proposal for ICH GCP that reinforces Quality by Design and the critical to quality factors\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Trials Challenges in relation to COVID-19 - Pharmity\" \/>\n<meta property=\"og:description\" content=\"ICH GCP Renovation. The way forward | This article will explain the ICH revision proposal for ICH GCP that reinforces Quality by Design and the critical to quality factors\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharmity\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-16T16:31:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-03-16T16:54:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Leire Zu\u00f1iga\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leire Zu\u00f1iga\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/\"},\"author\":{\"name\":\"Leire Zu\u00f1iga\",\"@id\":\"https:\/\/www.pharmity.com\/#\/schema\/person\/a44b1c604f6554577cde3888acbaedb4\"},\"headline\":\"Clinical Trials Challenges in relation to COVID-19\",\"datePublished\":\"2020-03-16T16:31:02+00:00\",\"dateModified\":\"2020-03-16T16:54:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/\"},\"wordCount\":625,\"publisher\":{\"@id\":\"https:\/\/www.pharmity.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png\",\"articleSection\":[\"ICH GCP\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/\",\"url\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/\",\"name\":\"Clinical Trials Challenges in relation to COVID-19 - Pharmity\",\"isPartOf\":{\"@id\":\"https:\/\/www.pharmity.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png\",\"datePublished\":\"2020-03-16T16:31:02+00:00\",\"dateModified\":\"2020-03-16T16:54:01+00:00\",\"description\":\"ICH GCP Renovation. The way forward | This article will explain the ICH revision proposal for ICH GCP that reinforces Quality by Design and the critical to quality factors\",\"breadcrumb\":{\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#primaryimage\",\"url\":\"http:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png\",\"contentUrl\":\"http:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png\",\"width\":800,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.pharmity.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical Trials Challenges in relation to COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.pharmity.com\/#website\",\"url\":\"https:\/\/www.pharmity.com\/\",\"name\":\"Pharmity\",\"description\":\"Pharmacy + Quality\",\"publisher\":{\"@id\":\"https:\/\/www.pharmity.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.pharmity.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.pharmity.com\/#organization\",\"name\":\"Pharmity\",\"url\":\"https:\/\/www.pharmity.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.pharmity.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/www.pharmity.com\/wp-content\/uploads\/2018\/05\/P-on-top-1.png?fit=548%2C348&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/www.pharmity.com\/wp-content\/uploads\/2018\/05\/P-on-top-1.png?fit=548%2C348&ssl=1\",\"width\":548,\"height\":348,\"caption\":\"Pharmity\"},\"image\":{\"@id\":\"https:\/\/www.pharmity.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/pharmity\/\",\"https:\/\/www.pinterest.es\/pharmity\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.pharmity.com\/#\/schema\/person\/a44b1c604f6554577cde3888acbaedb4\",\"name\":\"Leire Zu\u00f1iga\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.pharmity.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/388f413783e9c9d3a6773d6ed98aeceb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/388f413783e9c9d3a6773d6ed98aeceb?s=96&d=mm&r=g\",\"caption\":\"Leire Zu\u00f1iga\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Trials Challenges in relation to COVID-19 - Pharmity","description":"ICH GCP Renovation. The way forward | This article will explain the ICH revision proposal for ICH GCP that reinforces Quality by Design and the critical to quality factors","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"Clinical Trials Challenges in relation to COVID-19 - Pharmity","og_description":"ICH GCP Renovation. The way forward | This article will explain the ICH revision proposal for ICH GCP that reinforces Quality by Design and the critical to quality factors","og_url":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/","og_site_name":"Pharmity","article_published_time":"2020-03-16T16:31:02+00:00","article_modified_time":"2020-03-16T16:54:01+00:00","og_image":[{"width":800,"height":800,"url":"https:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png","type":"image\/png"}],"author":"Leire Zu\u00f1iga","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Leire Zu\u00f1iga","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#article","isPartOf":{"@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/"},"author":{"name":"Leire Zu\u00f1iga","@id":"https:\/\/www.pharmity.com\/#\/schema\/person\/a44b1c604f6554577cde3888acbaedb4"},"headline":"Clinical Trials Challenges in relation to COVID-19","datePublished":"2020-03-16T16:31:02+00:00","dateModified":"2020-03-16T16:54:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/"},"wordCount":625,"publisher":{"@id":"https:\/\/www.pharmity.com\/#organization"},"image":{"@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#primaryimage"},"thumbnailUrl":"http:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png","articleSection":["ICH GCP"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/","url":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/","name":"Clinical Trials Challenges in relation to COVID-19 - Pharmity","isPartOf":{"@id":"https:\/\/www.pharmity.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#primaryimage"},"thumbnailUrl":"http:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png","datePublished":"2020-03-16T16:31:02+00:00","dateModified":"2020-03-16T16:54:01+00:00","description":"ICH GCP Renovation. The way forward | This article will explain the ICH revision proposal for ICH GCP that reinforces Quality by Design and the critical to quality factors","breadcrumb":{"@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#primaryimage","url":"http:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png","contentUrl":"http:\/\/www.pharmity.com\/wp-content\/uploads\/2020\/03\/Yellow-and-Gray-Just-Sold-Real-Estate-Social-Media-Graphic.png","width":800,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.pharmity.com\/clinical-trials-challenges-in-relation-to-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pharmity.com\/"},{"@type":"ListItem","position":2,"name":"Clinical Trials Challenges in relation to COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.pharmity.com\/#website","url":"https:\/\/www.pharmity.com\/","name":"Pharmity","description":"Pharmacy + Quality","publisher":{"@id":"https:\/\/www.pharmity.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pharmity.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.pharmity.com\/#organization","name":"Pharmity","url":"https:\/\/www.pharmity.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pharmity.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/www.pharmity.com\/wp-content\/uploads\/2018\/05\/P-on-top-1.png?fit=548%2C348&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.pharmity.com\/wp-content\/uploads\/2018\/05\/P-on-top-1.png?fit=548%2C348&ssl=1","width":548,"height":348,"caption":"Pharmity"},"image":{"@id":"https:\/\/www.pharmity.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/pharmity\/","https:\/\/www.pinterest.es\/pharmity\/"]},{"@type":"Person","@id":"https:\/\/www.pharmity.com\/#\/schema\/person\/a44b1c604f6554577cde3888acbaedb4","name":"Leire Zu\u00f1iga","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pharmity.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/388f413783e9c9d3a6773d6ed98aeceb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/388f413783e9c9d3a6773d6ed98aeceb?s=96&d=mm&r=g","caption":"Leire Zu\u00f1iga"}}]}},"_links":{"self":[{"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/posts\/647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/comments?post=647"}],"version-history":[{"count":11,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/posts\/647\/revisions"}],"predecessor-version":[{"id":659,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/posts\/647\/revisions\/659"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/media\/656"}],"wp:attachment":[{"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/media?parent=647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/categories?post=647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharmity.com\/wp-json\/wp\/v2\/tags?post=647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}